Talazoparib
Metastatic Prostate Carcinoma
Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Fundacion Oncosur
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06582628CT.gov Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC) | — | Recruiting | — | — | — |
NCT04824937CT.gov Telaglenastat + Talazoparib In Prostate Cancer | — | Unknown | — | — | — |
NCT04846478CT.gov Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | — | Active Not Recruiting | — | — | — |
NCT04550494CT.gov Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | — | Recruiting | — | — | — |
NCT04703920CT.gov Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | — | Completed | — | — | — |
NCT04332744CT.gov Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) | — | Completed | — | — | — |
NCT04019327CT.gov A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | — | Completed | — | — | — |
NCT05650476CT.gov Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076) | — | Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Talazoparib (this asset) | Fundacion Oncosur | P2 | B · 60 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Sipuleucel-T | Yale University | P2 | BB |
| Carboplatin | Case Comprehensive Cancer Center | P3 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Talazoparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| BRCA2-Related Cancer Predisposition | — | P3 | BB · 68 |
| Castration-Resistant Prostate Carcinoma | — | P2 | BB · 65 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Talazoparib in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/talazoparib-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →